Full Text View
Tabular View
No Study Results Posted
Related Studies
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
This study has been completed.
Study NCT01259323   Information provided by Regeneron Pharmaceuticals

First Received on December 10, 2010.   Last Updated on October 2, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Dermatitis
Additional conditions recognized in this trial
Dermatitis, Atopic
More general conditions related to this trial
Genetic Diseases, Inborn
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Skin Diseases
Skin Diseases, Eczematous
Skin Diseases, Genetic
Interventions listed in this trial
REGN668
Sponsors listed in this trial
Regeneron Pharmaceuticals
Sanofi


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services